Debra J. Tompson
R&d
Stevenage, ENG, United Kingdom
Stevenage, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Physiologically Based Pharmacokinetic Modeling of Phosphate Prodrugs─Case Studies: Fostemsavir and Fostamatinib.
Journal: Molecular pharmaceutics
Published: March 26, 2025
Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
Journal: Dermatology and therapy
Published: November 07, 2023
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab.
Journal: Journal of pharmacokinetics and pharmacodynamics
Published: July 21, 2023
Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug.
Journal: CPT: pharmacometrics & systems pharmacology
Published: October 06, 2022
A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.
Journal: BMJ open gastroenterology
Published: April 09, 2021
Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology.
Journal: Pharmaceutical research
Published: March 08, 2021
Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772.
Journal: Pharmaceutical research
Published: February 18, 2021
Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects.
Journal: European journal of drug metabolism and pharmacokinetics
Published: November 09, 2020
A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.
Journal: Arthritis research & therapy
Published: October 21, 2020
Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled Study.
Journal: Clinical pharmacology and therapeutics
Published: October 28, 2019
Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
Journal: Pharmacology research & perspectives
Published: September 18, 2017
Adolescent Clinical Development of Ezogabine/Retigabine as Adjunctive Therapy for Partial-Onset Seizures: Pharmacokinetics and Tolerability.
Journal: The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
Published: November 24, 2016
Last Updated: 09/26/2026